Distinguished in Squamous Cell Lung Carcinoma

Dr. Jeffrey M. Clarke

Oncology
Duke Health
Duke Health Integrated Practice Inc
6301 Herndon Rd, 
Durham, NC 
Accepting New Patients
Offers Telehealth
Distinguished in Squamous Cell Lung Carcinoma
Duke Health
Duke Health Integrated Practice Inc
6301 Herndon Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Clarke is an Oncologist in Durham, North Carolina. Dr. Clarke is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Clarke is currently accepting new patients.

His clinical research consists of co-authoring 67 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Squamous Cell Lung Carcinoma.

Specialties
Oncology
Licenses
Student in an Organized Health Care Education/Training Program in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Piedmont
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
6301 Herndon Rd, Durham, NC 27713
Call: 919-684-8111
Other Locations
DUKE HEALTH INTEGRATED PRACTICE INC
20 Duke Medicine Cir, Durham, NC 27710
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2351 Erwin Rd, Durham, NC 27705
Call: 919-684-8111
DUKE HEALTH INTEGRATED PRACTICE INC
2301 Erwin Rd, Durham, NC 27705
Call: 919-684-8111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Genetic
Study Phase: Phase 1
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drug: GT103
Study Phase: Phase 1
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2024
Intervention Type: Genetic, Radiation
Study Drug: Autologous Genetically Modified MAGE-A4c1032 T-Cells
Study Phase: Phase 1
View 8 Less Clinical Trials
Similar Doctors
Distinguished in Squamous Cell Lung Carcinoma
Dr. Thomas E. Stinchcombe
Oncology | Hematology Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Thomas E. Stinchcombe
Oncology | Hematology Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (7.0 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Stinchcombe is an Oncologist and a Hematologist Oncology provider in Durham, North Carolina. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (7.0 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Crawford is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Crawford is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Praveen Namireddy
Hematology Oncology | Hematology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Praveen Namireddy
Hematology Oncology | Hematology | Oncology

Wakemed Specialists Group LLC

3000 New Bern Ave, 
Raleigh, NC 
 (21.1 miles away)
919-350-7270
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Praveen Namireddy is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Namireddy is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Namireddy is currently accepting new patients.

VIEW MORE SQUAMOUS CELL LUNG CARCINOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clarke's expertise for a condition
ConditionClose
  • Elite
  • Lung Cancer
    Dr. Clarke is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Clarke is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Clarke is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Clarke is
    Distinguished
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Clarke is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Lung Adenocarcinoma
    Dr. Clarke is
    Distinguished
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Mesothelioma
    Dr. Clarke is
    Distinguished
    . Learn about Mesothelioma.
    See more Mesothelioma experts
  • Pleuropulmonary Blastoma
    Dr. Clarke is
    Distinguished
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
View All 8 Distinguished Conditions
  • Advanced
  • Metastatic Brain Tumor
    Dr. Clarke is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Metastatic Pleural Tumor
    Dr. Clarke is
    Advanced
    . Learn about Metastatic Pleural Tumor.
    See more Metastatic Pleural Tumor experts
  • Posterior Fossa Tumor
    Dr. Clarke is
    Advanced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Clarke is
    Advanced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
  • Experienced
  • Brain Tumor
    Dr. Clarke is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Colorectal Cancer
    Dr. Clarke is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Lung Nodules
    Dr. Clarke is
    Experienced
    . Learn about Lung Nodules.
    See more Lung Nodules experts
  • Lymphofollicular Hyperplasia
    Dr. Clarke is
    Experienced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
  • Melanoma
    Dr. Clarke is
    Experienced
    . Learn about Melanoma.
    See more Melanoma experts
  • Neuroendocrine Tumor
    Dr. Clarke is
    Experienced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.